<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041638</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01997</org_study_id>
    <secondary_id>NCI-2011-01997</secondary_id>
    <secondary_id>COG-ANBL0931</secondary_id>
    <secondary_id>CDR0000662673</secondary_id>
    <secondary_id>ANBL0931</secondary_id>
    <secondary_id>ANBL0931</secondary_id>
    <secondary_id>ANBL0931</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT01041638</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma</brief_title>
  <official_title>A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18
      together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
      transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18,
      may find tumor cells and help kill them. Colony-stimulating factors, such as sargramostim,
      may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin
      may stimulate the white blood cells to kill tumor cells. Isotretinoin may help neuroblastoma
      cells become more like normal cells, and to grow and spread more slowly. Giving monoclonal
      antibody Ch14.18 with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
      transplant may be an effective treatment for neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To comprehensively define the safety profile of ch14.18 when administered with cytokines
      and isotretinoin in high-risk neuroblastoma patients after autologous stem cell transplant
      (ASCT).

      SECONDARY OBJECTIVES:

      I. To further describe and refine the event-free survival (EFS) and overall survival (OS)
      estimates and baseline characteristics for subjects receiving chl4.18 + cytokines +
      isotretinoin.

      II. To further describe the safety and toxicity of chl4.18 + cytokines + isotretinoin with
      focus on: a) number of courses delivered per patient; b) number of dose reductions or
      stoppage (ch14.18 and/or interleukin [IL]-2 [aldesleukin]); and c) number of toxic deaths.

      III. To further describe the immune reconstitution of patients following ASCT, based on
      laboratory data obtained just prior to, during, and after treatment with this regimen.

      IV. To obtain correlative laboratory data to evaluate and describe mechanisms related to
      response, toxicity of immune activation, and allergic phenomena.

      OUTLINE:

      Patients receive sargramostim subcutaneously (SC) or intravenously (IV) over 2 hours on days
      0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of
      courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin orally (PO) twice
      daily (BID) on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days
      10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and
      on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the
      absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed up every 3 months for 1 year, every
      6 months for 4 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever).</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Designed to collect comprehensive safety/toxicity data, as well as additional efficacy data for the immunotherapy. To address the primary objective, descriptive analyses summarizing the number and type of AEs will be performed. The percentage of patients reporting each unacceptable (Grade 3 or higher) CTC toxicity code, tabulated by course, are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>From enrollment until the first occurrence of relapse, progressive disease, secondary malignancy, or death, or until last contact if no event occurred, up to 5 years</time_frame>
    <description>Estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From enrollment until death, or until last contact with the patient, up to 5 years</time_frame>
    <description>Estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Localized Resectable Neuroblastoma</condition>
  <condition>Localized Unresectable Neuroblastoma</condition>
  <condition>Regional Neuroblastoma</condition>
  <condition>Stage 4 Neuroblastoma</condition>
  <condition>Stage 4S Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dinutuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
    <other_name>Ch 14.18UTC</other_name>
    <other_name>Ch14.18</other_name>
    <other_name>MOAB Ch14.18</other_name>
    <other_name>monoclonal antibody Ch14.18</other_name>
    <other_name>Unituxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
    <other_name>13-cis retinoic acid</other_name>
    <other_name>13-cis-Retinoate</other_name>
    <other_name>13-cis-Retinoic Acid</other_name>
    <other_name>13-cis-Vitamin A Acid</other_name>
    <other_name>13-cRA</other_name>
    <other_name>Accure</other_name>
    <other_name>Accutane</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>cis-Retinoic Acid</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Isotretinoinum</other_name>
    <other_name>Isotrex</other_name>
    <other_name>Isotrexin</other_name>
    <other_name>Neovitamin A</other_name>
    <other_name>Neovitamin A Acid</other_name>
    <other_name>Oratane</other_name>
    <other_name>Retinoicacid-13-cis</other_name>
    <other_name>Ro 4-3780</other_name>
    <other_name>Ro-4-3780</other_name>
    <other_name>Roaccutan</other_name>
    <other_name>Roaccutane</other_name>
    <other_name>Roacutan</other_name>
    <other_name>Sotret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must be diagnosed with neuroblastoma, and categorized as high-risk at the
             time of diagnosis

          -  At pre-ASCT evaluation, patients must meet the International Neuroblastoma Response
             Criteria (INRC) for complete response (CR), very good partial response (VGPR), or
             partial response (PR) for primary site, soft tissue metastases and bone metastases;
             patients who meet those criteria must also meet the protocol specified criteria for
             bone marrow response as outlined below: =&lt; 10% tumor (of total nucleated cellular
             content) seen on any specimen from a bilateral bone marrow aspirate/biopsy; patients
             who have no tumor seen on the prior bone marrow, and then have =&lt; 10% tumor on any of
             the bilateral marrow aspirate/biopsy specimens done at pre-ASCT and/or pre-enrollment
             evaluation will also be eligible; (Note that, per INRC, this would have been defined
             as an &quot;overall&quot; response of progressive disease [PD])

          -  Prior to enrollment on ANBL0931, a determination of residual disease must be performed
             (tumor imaging studies including metaiodobenzylguanidine [MIBG] scan, computed
             tomography [CT] or magnetic resonance imaging [MRI], bone marrow aspiration and
             biopsy); this disease assessment is required for eligibility, and should be done
             preferably within 2 weeks but must be done within a maximum of 4 weeks before
             enrollment

               -  Patients with residual disease are eligible; biopsy is not required

               -  Patients must not have progressive disease except for protocol specified bone
                  marrow response

          -  All patients must have completed therapy including intensive induction chemotherapy
             followed by ASCT and radiotherapy to be eligible; radiotherapy may be waived for
             patients who either had a small adrenal mass which was completely resected upfront, or
             who never had an identifiable primary tumor

          -  No more than 9 months from the date of starting the first induction chemotherapy after
             diagnosis to the date of ASCT except for the rare occasions as noted below; for tandem
             ASCT patients, this will be the date of the FIRST stem cell infusion; Exception: for
             those who are initially diagnosed as non-high risk neuroblastoma, but later converted
             (and/ or relapsed) to high risk neuroblastoma, the 9 months restriction should start
             from the date of induction therapy for high risk neuroblastoma (not from the initial
             induction therapy for non-high risk disease), to the date of ASCT

          -  Use Karnofsky for patients &gt; 16 years of age and Lansky for patients =&lt; 16 years of
             age; required patients must have a Lansky or Karnofsky performance scale score of &gt;=
             50%

          -  Patients must have a life expectancy of &gt;= 2 months (8 weeks)

          -  Total absolute phagocyte count (APC = neutrophils + monocytes) is at least 1000/uL

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  1 month to &lt; 6 months: 0.4 mg/dL

               -  6 months to &lt; 1 year: 0.5 mg/dL

               -  1 to &lt; 2 years: 0.6 mg/dL

               -  2 to &lt; 6 years: 0.8 mg/dL

               -  6 to &lt; 10 years: 1 mg/dL

               -  10 to &lt; 13 years: 1.2 mg/dL

               -  13 to &lt; 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)

               -  &gt;= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 5 x
             upper limit of normal (ULN) for age

          -  SOS (sinusoidal obstruction syndrome, formerly known as veno-occlusive disease [VOD]),
             if present, should be stable or improving

          -  Shortening fraction of &gt;= 27% by echocardiogram, or ejection fraction of &gt;= 55% by
             radionuclide angiography

          -  No evidence of dyspnea at rest

          -  If pulmonary function tests (PFTs) are performed, forced expiratory volume in one
             second (FEV1)/forced vital capacity (FVC) &gt; 60% by pulmonary function test

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and well
             controlled

          -  Central nervous system (CNS) toxicity &lt; grade 2

        Exclusion Criteria:

          -  Females of childbearing potential must have a negative pregnancy test

          -  Patients of childbearing potential must agree to use an effective birth control method

          -  Female patients who are lactating must agree to stop breast-feeding

          -  Patients must not have received prior anti-GD2 antibody therapy

          -  Patients must not have received prior vaccine therapy administered as treatment of
             neuroblastoma not routine infectious disease vaccinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Ozkaynak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University/Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>December 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2015</results_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin</title>
          <description>Patients receive sargramostim subcutaneously or IV over 2 hours on days 0-13 of courses 1, 3, and 5 (dose: 250 micrograms/m²/dose); monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4 (dose: 25 mg/m2/dose); and oral isotretinoin twice daily on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5 (Weight based dosage: &gt; 12 kg: 80 mg/m2/dose BID; total daily dose 160 mg/m2/day, divided BID. ≤ 12 kg: 2.67 mg/kg/dose BID; total daily dose is 5.33 mg/kg/day, divided BID. Round dose up to the nearest 10 mg). Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4 (actual dosage is body surface area based and varies by course). Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin</title>
          <description>Patients receive sargramostim subcutaneously or IV over 2 hours on days 0-13 of courses 1, 3, and 5 (dose: 250 micrograms/m²/dose); monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4 (dose: 25 mg/m2/dose); and oral isotretinoin twice daily on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5 (Weight based dosage: &gt; 12 kg: 80 mg/m2/dose BID; total daily dose 160 mg/m2/day, divided BID. ≤ 12 kg: 2.67 mg/kg/dose BID; total daily dose is 5.33 mg/kg/day, divided BID. Round dose up to the nearest 10 mg). Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4 (actual dosage is body surface area based and varies by course). Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever).</title>
        <description>Designed to collect comprehensive safety/toxicity data, as well as additional efficacy data for the immunotherapy. To address the primary objective, descriptive analyses summarizing the number and type of AEs will be performed. The percentage of patients reporting each unacceptable (Grade 3 or higher) CTC toxicity code, tabulated by course, are reported.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>There was one patient that did not receive treatment, represented on the baseline form as &quot;withdrawal by patient&quot;, not included in outcome measure tabulation.</population>
        <group_list>
          <group group_id="O1">
            <title>Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin</title>
            <description>Patients receive sargramostim subcutaneously or IV over 2 hours on days 0-13 of courses 1, 3, and 5 (dose: 250 micrograms/m²/dose); monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4 (dose: 25 mg/m2/dose); and oral isotretinoin twice daily on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5 (Weight based dosage: &gt; 12 kg: 80 mg/m2/dose BID; total daily dose 160 mg/m2/day, divided BID. ≤ 12 kg: 2.67 mg/kg/dose BID; total daily dose is 5.33 mg/kg/day, divided BID. Round dose up to the nearest 10 mg). Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4 (actual dosage is body surface area based and varies by course). Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome, or Fever).</title>
          <description>Designed to collect comprehensive safety/toxicity data, as well as additional efficacy data for the immunotherapy. To address the primary objective, descriptive analyses summarizing the number and type of AEs will be performed. The percentage of patients reporting each unacceptable (Grade 3 or higher) CTC toxicity code, tabulated by course, are reported.</description>
          <population>There was one patient that did not receive treatment, represented on the baseline form as &quot;withdrawal by patient&quot;, not included in outcome measure tabulation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal pain (10300), course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (10300), course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (10300), course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (10300), course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (10300), course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain (10300), course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic reaction (12000), Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anal pain (12800), Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaphylaxis (13100), Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain (16200), Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capillary leak syndrome (19800) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall pain (21400) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (33900) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain (34200) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension (43600) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck pain (57800) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain (58600) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (60600) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity (60700) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral sensory neuropathy (64100) - Course 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>Estimated using Kaplan-Meier curves.</description>
        <time_frame>From enrollment until the first occurrence of relapse, progressive disease, secondary malignancy, or death, or until last contact if no event occurred, up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated using Kaplan-Meier curves.</description>
        <time_frame>From enrollment until death, or until last contact with the patient, up to 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>SAE field contains NCI CTCAEs submitted via expedited reporting (NCI AdEERs / CAeRs). The AE field contains grade 3 and higher CTCAEs reported on study excluding those that were reported as SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chimeric Antibody 14.18 With GM-CSF, IL-2 and Isotretinoin</title>
          <description>Patients receive sargramostim subcutaneously or IV over 2 hours on days 0-13 of courses 1, 3, and 5 (dose: 250 micrograms/m²/dose); monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4 (dose: 25 mg/m2/dose); and oral isotretinoin twice daily on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5 (Weight based dosage: &gt; 12 kg: 80 mg/m2/dose BID; total daily dose 160 mg/m2/day, divided BID. ≤ 12 kg: 2.67 mg/kg/dose BID; total daily dose is 5.33 mg/kg/day, divided BID. Round dose up to the nearest 10 mg). Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4 (actual dosage is body surface area based and varies by course). Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="148" subjects_affected="65" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>18100-Bone marrow hypocellular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>33300-Febrile neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20000-Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74500-Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>28000-Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38900-Hearing impaired</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="56" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>12800-Anal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>22100-Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>22400-Colonic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25700-Diarrhea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>27600-Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>44200-Ileal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53900-Malabsorption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57600-Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>81900-Typhlitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>87900-Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>28200-Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>33900-Fever</sub_title>
                <counts group_id="E1" events="204" subjects_affected="69" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>48700-Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58600-Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="134" subjects_affected="46" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>12000-Allergic reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>13100-Anaphylaxis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24400-Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="63" subjects_affected="33" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25600-Device related infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29500-Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60100-Otitis media</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>75200-Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76000-Small intestine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>82300-Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83100-Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>86400-Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="24" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>11800-Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24100-Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53700-Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="339" subjects_affected="78" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53800-Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="193" subjects_affected="55" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="355" subjects_affected="58" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83600-Urine output decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88200-Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="82" subjects_affected="25" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24700-Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41400-Hyperglycemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41700-Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42400-Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42900-Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="117" subjects_affected="51" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="42" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>16200-Back pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21400-Chest wall pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>34200-Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57800-Neck pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60700-Pain in extremity</sub_title>
                <counts group_id="E1" events="34" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>15300-Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25300-Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38800-Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42000-Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58200-Neuralgia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>59000-Oculomotor nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>63900-Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>64100-Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76700-Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>11400-Agitation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>13700-Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25000-Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38500-Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68300-Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83000-Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>14100-Apnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>19300-Bronchospasm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23800-Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>27800-Dyspnea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="29" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68700-Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>78100-Stridor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88400-Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>26200-Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>63600-Periorbital edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68400-Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>69700-Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>84100-Urticaria</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>79000-Surgical and medical procedures - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>19800-Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="67" subjects_affected="33" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="1181" subjects_affected="99" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>17200-Blood and lymphatic system disorders - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>18100-Bone marrow hypocellular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25800-Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20100-Cardiac disorders - Other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21300-Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>61000-Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>63100-Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74200-Sinus bradycardia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74500-Sinus tachycardia</sub_title>
                <counts group_id="E1" events="740" subjects_affected="85" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>78900-Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>81400-Tricuspid valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>27900-Ear and labyrinth disorders - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>28000-Ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>31600-External ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38900-Hearing impaired</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>11200-Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29200-Endocrine disorders - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41900-Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42200-Hyperthyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43400-Hypoparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43800-Hypothyroidism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>17800-Blurred vision</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23200-Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>26000-Dry eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>31900-Eye disorders - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>32100-Eye pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>32200-Eyelid function disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>59300-Optic nerve disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>61900-Papilledema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65600-Photophobia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>73200-Scleral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10100-Abdominal distension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="284" subjects_affected="70" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>12800-Anal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>17100-Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21200-Cheilitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>22100-Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23400-Constipation</sub_title>
                <counts group_id="E1" events="72" subjects_affected="36" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25700-Diarrhea</sub_title>
                <counts group_id="E1" events="203" subjects_affected="60" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>26100-Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>27500-Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>27600-Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29400-Enterocolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>34400-Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>36400-Gastritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>36500-Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>36700-Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>36900-Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37600-Gingival pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>39800-Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57600-Nausea</sub_title>
                <counts group_id="E1" events="188" subjects_affected="55" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>59700-Oral pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>70800-Rectal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>77900-Stomach pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>80200-Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>87900-Vomiting</sub_title>
                <counts group_id="E1" events="309" subjects_affected="65" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>21500-Chills</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>28200-Edema face</sub_title>
                <counts group_id="E1" events="110" subjects_affected="56" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>28300-Edema limbs</sub_title>
                <counts group_id="E1" events="61" subjects_affected="36" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>28400-Edema trunk</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>32500-Facial pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>33200-Fatigue</sub_title>
                <counts group_id="E1" events="73" subjects_affected="34" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>33900-Fever</sub_title>
                <counts group_id="E1" events="1117" subjects_affected="102" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>34600-Flu like symptoms</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>35000-Gait disturbance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43700-Hypothermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>45000-Infusion related reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>45200-Injection site reaction</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>48700-Irritability</sub_title>
                <counts group_id="E1" events="74" subjects_affected="33" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>52800-Localized edema</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>54000-Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58600-Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="746" subjects_affected="82" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>12000-Allergic reaction</sub_title>
                <counts group_id="E1" events="123" subjects_affected="33" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24400-Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>18800-Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23300-Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29500-Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>30400-Esophageal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>55500-Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57200-Nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60100-Otitis media</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>62000-Papulopustular rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>62200-Paronychia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65200-Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>72600-Rhinitis infective</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74600-Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>75200-Skin infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76000-Small intestine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>82300-Upper respiratory infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83100-Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>19400-Bruising</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25500-Dermatitis radiation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>45700-Injury poisoning and procedural complications - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>66800-Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>86400-Vascular access complication</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="507" subjects_affected="90" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>11800-Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="64" subjects_affected="20" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="399" subjects_affected="91" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21700-Cholesterol high</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24100-Creatinine increased</sub_title>
                <counts group_id="E1" events="137" subjects_affected="31" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>28700-Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="87" subjects_affected="20" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>39400-Hemoglobin increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>45800-INR increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>48400-Investigations - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53700-Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="904" subjects_affected="87" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>53800-Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="376" subjects_affected="67" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="780" subjects_affected="97" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88200-Weight gain</sub_title>
                <counts group_id="E1" events="227" subjects_affected="56" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="54" subjects_affected="21" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="737" subjects_affected="89" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="32" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>24700-Dehydration</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="26" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41400-Hyperglycemia</sub_title>
                <counts group_id="E1" events="195" subjects_affected="61" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="71" subjects_affected="35" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41700-Hypermagnesemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="17" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42400-Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="205" subjects_affected="84" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42500-Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="890" subjects_affected="101" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="579" subjects_affected="96" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42900-Hypoglycemia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="43" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="392" subjects_affected="85" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43200-Hypomagnesemia</sub_title>
                <counts group_id="E1" events="119" subjects_affected="41" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="524" subjects_affected="95" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="211" subjects_affected="69" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>54900-Metabolism and nutrition disorders - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>14700-Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>16200-Back pain</sub_title>
                <counts group_id="E1" events="70" subjects_affected="25" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>18200-Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>19700-Buttock pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21400-Chest wall pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>37300-Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>49800-Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>55900-Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>56300-Musculoskeletal and connective tissue disorder - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>56500-Myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57800-Neck pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="14" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60700-Pain in extremity</sub_title>
                <counts group_id="E1" events="155" subjects_affected="48" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>11500-Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>22000-Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>22800-Concentration impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25300-Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25900-Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38800-Headache</sub_title>
                <counts group_id="E1" events="76" subjects_affected="31" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42000-Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>51800-Lethargy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>54400-Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>54500-Meningismus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>55400-Movements involuntary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58100-Nervous system disorders - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58200-Neuralgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>58700-Nystagmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>59000-Oculomotor nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>62100-Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>64100-Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>73600-Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76700-Somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>81300-Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>67200-Premature delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>11400-Agitation</sub_title>
                <counts group_id="E1" events="40" subjects_affected="24" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>13700-Anxiety</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23000-Confusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>25400-Depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>38500-Hallucinations</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>45900-Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>54100-Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68500-Psychiatric disorders - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>71700-Restlessness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>21800-Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>39300-Hematuria</sub_title>
                <counts group_id="E1" events="93" subjects_affected="36" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68300-Proteinuria</sub_title>
                <counts group_id="E1" events="144" subjects_affected="43" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>71000-Renal and urinary disorders - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>82800-Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>82900-Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83000-Urinary retention</sub_title>
                <counts group_id="E1" events="63" subjects_affected="30" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83300-Urinary tract pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83400-Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>83500-Urine discoloration</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>37400-Genital edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>62600-Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>62900-Penile pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>71400-Reproductive system and breast disorders - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>85600-Vaginal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>12100-Allergic rhinitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>15400-Atelectasis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>19000-Bronchial stricture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>19300-Bronchospasm</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>23800-Cough</sub_title>
                <counts group_id="E1" events="220" subjects_affected="74" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>27800-Dyspnea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29700-Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>40700-Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41000-Hoarseness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="99" subjects_affected="32" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>51500-Laryngopharyngeal dysesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>51600-Laryngospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57500-Nasal congestion</sub_title>
                <counts group_id="E1" events="39" subjects_affected="23" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65300-Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65900-Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>66200-Pleuritic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>66300-Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>66700-Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>67600-Productive cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68700-Pulmonary edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="242" subjects_affected="34" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>72200-Retinoic acid syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76200-Sneezing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>76800-Sore throat</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>88400-Wheezing</sub_title>
                <counts group_id="E1" events="37" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>12200-Alopecia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="28" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>19500-Bullous dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>26200-Dry skin</sub_title>
                <counts group_id="E1" events="175" subjects_affected="69" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>29900-Erythema multiforme</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42300-Hypertrichosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>57300-Nail loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>60900-Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>63600-Periorbital edema</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>65700-Photosensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>68400-Pruritus</sub_title>
                <counts group_id="E1" events="223" subjects_affected="62" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>69600-Rash acneiform</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>69700-Rash maculo-papular</sub_title>
                <counts group_id="E1" events="130" subjects_affected="58" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74700-Skin and subcutaneous tissue disorders - Other</sub_title>
                <counts group_id="E1" events="51" subjects_affected="20" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74800-Skin atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>74900-Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>75000-Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>75100-Skin induration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>75300-Skin ulceration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>84100-Urticaria</sub_title>
                <counts group_id="E1" events="139" subjects_affected="46" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>19800-Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="131" subjects_affected="53" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>34700-Flushing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>41100-Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="406" subjects_affected="56" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="768" subjects_affected="81" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>79600-Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>86500-Vascular disorders - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

